DOXYCYCLINE AS POTENT INHIBITOR OF COVID -19 MAIN PROTEASE: IN-SILICO DOCKING APPROACH
Dr. Bhagwan Nautiyal, Amit Kumar and Jitender K. Malik*
ABSTRACT
Corona virus (COVID-19) is an enveloped RNA virus that is diversely initiates in humans and wildlife. A total of 6 species have been identified to cause disease in humans. Viral infections play a critical role in human diseases, and recent outbreaks is the influx worldwide in form of novel corona .The SS-RNA virus from the enveloped corona virus family caused SARS (Severe acute respiratory syndrome) which is life threatening viral infection. The spreading of infection is quick in many countries of the world. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are numerous drug trials going on with some positive results. Though, since no vaccine is available, the best way to fight the virus is by preventive measures. In the present research an attempt had been made to find new COVID-19 main protease inhibitor by molecular docking approach. Doxycycline is an associate of the tetracycline class of antibiotics and has been used clinically for more than 40 years. It is a useful antibiotic for prophylaxis against and treatment of several important potential biological combat agents. Doxycycline was taken as drug which follows Lippinski’s rule of five, thus having very good drug score as well as drug likeness score. The present study reveals that Doxycycline has good binding affinity with COVID-19 protease and thus can be used as prophylaxis and therapeutic treatment for corona patient.
Keywords: COVID-19, Doxycycline, Molecular Docking & Prevention measures.
[Full Text Article]
Impact Factor : 6.044
